newsfilter
← Latest News
Business Wire·

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment Full enrollment expected by Q2 2026 with plans to seek early approval at that time based on early tumor